EP2948450A4 - Composés inhibiteurs de métalloenzyme - Google Patents
Composés inhibiteurs de métalloenzymeInfo
- Publication number
- EP2948450A4 EP2948450A4 EP14742899.9A EP14742899A EP2948450A4 EP 2948450 A4 EP2948450 A4 EP 2948450A4 EP 14742899 A EP14742899 A EP 14742899A EP 2948450 A4 EP2948450 A4 EP 2948450A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- inhibitor compounds
- metalloenzyme inhibitor
- metalloenzyme
- compounds
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 229940125956 metalloenzyme inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361757594P | 2013-01-28 | 2013-01-28 | |
PCT/US2014/013204 WO2014117090A1 (fr) | 2013-01-28 | 2014-01-27 | Composés inhibiteurs de métalloenzyme |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2948450A1 EP2948450A1 (fr) | 2015-12-02 |
EP2948450A4 true EP2948450A4 (fr) | 2016-11-09 |
Family
ID=51228112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14742899.9A Withdrawn EP2948450A4 (fr) | 2013-01-28 | 2014-01-27 | Composés inhibiteurs de métalloenzyme |
Country Status (6)
Country | Link |
---|---|
US (1) | US9663488B2 (fr) |
EP (1) | EP2948450A4 (fr) |
JP (1) | JP2016508487A (fr) |
AU (1) | AU2014209107B2 (fr) |
CA (1) | CA2898615A1 (fr) |
WO (1) | WO2014117090A1 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA026209B1 (ru) * | 2012-01-20 | 2017-03-31 | Ваймет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
AU2015231208B2 (en) | 2014-03-19 | 2019-04-04 | Mycovia Pharmaceuticals, Inc. | Antifungal compound process |
US10000465B2 (en) | 2014-03-19 | 2018-06-19 | Mycovia Pharmaceuticals, Inc. | Antifungal compound process |
EP3119764B1 (fr) | 2014-03-19 | 2019-04-17 | Viamet Pharmaceuticals (NC), Inc. | Procédé de préparation d'un composé antifongique |
EP3119756B9 (fr) | 2014-03-19 | 2021-08-25 | Dow AgroSciences LLC | 2-(2,4-difluorophényl)-1,1-difluoro-1-(5-substitution-pyridine-2-yl)-3-(1h-tetrazol-1-yl)propane-2-oles et procédés de préparation correspondants |
JP6613391B2 (ja) | 2014-03-19 | 2019-12-04 | ブイピーエス‐3,インコーポレイテッド | 2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(5−置換ピリジン−2−イル)−3−(1h−テトラゾール−1−イル)プロパン−2−オールおよびその調製工程 |
EP3119754A4 (fr) | 2014-03-19 | 2017-12-13 | Viamet Pharmaceuticals, Inc. | Préparation d'un composé antifongique |
WO2015143184A1 (fr) | 2014-03-19 | 2015-09-24 | Viamet Pharmaceuticals, Inc. | Procédé de préparation d'un composé antifongique |
JP2017507991A (ja) | 2014-03-19 | 2017-03-23 | ヴィアメット ファーマスーティカルズ,インコーポレイテッド | 抗真菌化合物の調製方法 |
WO2015143172A1 (fr) | 2014-03-19 | 2015-09-24 | Viamet Pharmaceuticals, Inc. | Procédé de préparation d'un composé antifongique |
JP6618530B2 (ja) | 2014-09-09 | 2019-12-11 | バイエル ファーマ アクチエンゲゼルシャフト | 置換n,2−ジアリールキノリン−4−カルボキサミドおよび抗炎症剤としてのその使用 |
CN107427506A (zh) | 2014-10-14 | 2017-12-01 | 拉霍拉敏感及免疫学研究所 | 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途 |
US10117864B2 (en) | 2015-03-18 | 2018-11-06 | Bayer Pharma Aktiengesellschaft | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof |
EA036098B1 (ru) | 2015-09-18 | 2020-09-28 | ВиПиЭс-3, ИНК. | Способ получения противогрибковых соединений |
CN105272896A (zh) * | 2015-10-19 | 2016-01-27 | 山东国润生物医药有限公司 | ((2s)-2-氮丙啶基)二苯基甲醇的制备方法 |
WO2017083434A1 (fr) | 2015-11-09 | 2017-05-18 | Forge Therapeutics, Inc. | Composés à base de pyrone pour traiter les infections bactériennes |
ES2909122T3 (es) | 2015-11-09 | 2022-05-05 | Forge Therapeutics Inc | Compuestos a base de hidroxipiridinona e hidroxipirimidinona para el tratamiento de infecciones bacterianas |
WO2017153234A1 (fr) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | N-cyclo-2-arylchinolin-4-carboxamides substitués et leur utilisation |
WO2017153235A1 (fr) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | N-cyclo-3-aryl-1-naphthamides substitués et leur utilisation |
WO2017153231A1 (fr) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | N-cyclo-2-arylisochinolinon-4-carboxamides substitués et leur utilisation |
JP2019142776A (ja) * | 2016-06-24 | 2019-08-29 | 石原産業株式会社 | N−(4−ピリジル)ベンズアミド化合物又はその塩を有効成分として含有する有害生物防除剤 |
HUE054272T2 (hu) | 2016-12-22 | 2021-09-28 | Calithera Biosciences Inc | Összetételek és módszerek az argináz-tevékenység gátlásához |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
AU2018251758B2 (en) | 2017-04-10 | 2021-11-18 | Bayer Aktiengesellschaft | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof |
US11066420B2 (en) * | 2017-05-01 | 2021-07-20 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof |
US11021471B2 (en) | 2017-05-10 | 2021-06-01 | Forge Therapeutics, Inc. | Antibacterial compounds |
BR112020026308A2 (pt) * | 2018-06-22 | 2021-03-30 | Ohio State Innovation Foundation | Compostos inibidores da di-hidro-orotato desidrogenase, composição farmacêutica que compreende os ditos compostos e uso dos mesmos para tratar câncer |
BR112021005044A2 (pt) | 2018-09-20 | 2021-06-08 | Forge Therapeutics, Inc. | compostos antibacterianos |
CN109456205B (zh) * | 2018-12-17 | 2021-09-21 | 石河子大学 | 以取代喹啉或异喹啉酰肼吡啶-n-氧化物为配体的水相体系中的n-芳基化方法 |
EP3725788A1 (fr) * | 2019-04-15 | 2020-10-21 | Bayer AG | Nouveaux composés azole d'aminoalkyle substitués par hétéroaryle en tant que pesticides |
US11731962B2 (en) | 2020-03-25 | 2023-08-22 | Blacksmith Medicines, Inc. | LpxC inhibitor and methods of making |
WO2023219456A1 (fr) * | 2022-05-12 | 2023-11-16 | 숙명여자대학교 산학협력단 | Substances inhibitrices d'histone désacétylase à base de quinoléine, leur procédé de préparation et composition pharmaceutique les comprenant en tant que principe actif |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008105515A1 (fr) * | 2007-02-28 | 2008-09-04 | Taisho Pharmaceutical Co., Ltd. | Nouveau dérivé d'acide hydroxamique |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA845594B (en) * | 1983-07-22 | 1986-03-26 | Du Pont | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
US4968702A (en) * | 1989-01-17 | 1990-11-06 | American Cyanamid Company | Substituted quinolinecarboxylic acids |
JPH083163A (ja) * | 1994-06-22 | 1996-01-09 | Kyowa Hakko Kogyo Co Ltd | 縮合ピリジン誘導体 |
ATE245156T1 (de) * | 1999-03-11 | 2003-08-15 | Neurogen Corp | Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden |
AR025929A1 (es) * | 1999-10-01 | 2002-12-18 | Inst Of Molecul & Cell Biology | Compuestos para el tratamiento de enfermedades mediadas por virus |
US6828329B2 (en) * | 2000-06-26 | 2004-12-07 | Neurogen Corporation | Aryl fused substituted 4-oxy-pyridines |
EP1337523B1 (fr) * | 2000-08-16 | 2005-10-19 | Neurogen Corporation | Derives pyridine 2,4-substitues |
US20040110802A1 (en) * | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
CA2540342A1 (fr) * | 2003-10-31 | 2005-05-12 | Neurogen Corporation | Agonistes des recepteurs de la capsicine |
MXPA06006532A (es) * | 2003-12-09 | 2006-08-23 | Vertex Pharma | Derivados de naftiridina y su uso como moduladores de receptores muscarinicos. |
WO2006034491A2 (fr) * | 2004-09-23 | 2006-03-30 | Bayer Pharmaceuticals Corporation | Composes a base de quinoleine et de quinazoline a substitution phenylique pour le traitement du diabete |
EP2001495A4 (fr) * | 2006-02-27 | 2010-12-08 | Alexander Michalow | Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations |
CN101084895B (zh) * | 2007-06-22 | 2011-11-23 | 复旦大学 | 一种葡萄球菌色氨酰-tRNA合成酶抑制剂 |
US20110015158A1 (en) | 2007-12-11 | 2011-01-20 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
WO2010024356A1 (fr) * | 2008-08-27 | 2010-03-04 | 大正製薬株式会社 | Nouveau dérivé de l’acide hydroxamique comportant un naphthyridine-n-oxyde |
WO2010094009A2 (fr) * | 2009-02-13 | 2010-08-19 | Children's Hospital Medical Center | Méthodes et compositions destinées au traitement de troubles associés au ras |
WO2011082245A2 (fr) | 2009-12-31 | 2011-07-07 | Viamet Pharmaceuticals, Inc. | Composés inhibiteurs de métallo-enzyme |
RU2450025C2 (ru) * | 2010-07-16 | 2012-05-10 | Учреждение Российской академии наук Институт высокомолекулярных соединений РАН | МЕТАЛЛ-ПОЛИМЕРНЫЙ КОМПЛЕКС ЕВРОПИЯ (Eu3+) И (СО)ПОЛИ-(МЕТИЛМЕТАКРИЛАТ)-(1-МЕТАКРИЛОИЛ-2-(2-ПИРИДИЛ)-4-КАРБОКСИХИНОЛИЛ)ГИДРАЗИНА |
BR112013014484A2 (pt) | 2010-12-13 | 2016-07-19 | Viamet Pharmaceuticals Inc | compostos inibidores de metaloenzimas |
EP2694481B1 (fr) * | 2011-04-08 | 2015-12-30 | Pfizer Inc | Dérivés d'imidazole, de pyrazole et de triazole, utiles en tant qu'agents antibactériens |
EP3067350B1 (fr) | 2011-06-19 | 2018-06-13 | Viamet Pharmaceuticals (NC), Inc. | Nouveaux composés inhibiteurs de métallo-enzyme |
EP2847168A1 (fr) * | 2012-05-10 | 2015-03-18 | Achaogen, Inc. | Agents antibactériens |
-
2014
- 2014-01-27 EP EP14742899.9A patent/EP2948450A4/fr not_active Withdrawn
- 2014-01-27 WO PCT/US2014/013204 patent/WO2014117090A1/fr active Application Filing
- 2014-01-27 AU AU2014209107A patent/AU2014209107B2/en not_active Revoked
- 2014-01-27 JP JP2015555384A patent/JP2016508487A/ja active Pending
- 2014-01-27 CA CA2898615A patent/CA2898615A1/fr not_active Abandoned
- 2014-01-27 US US14/763,468 patent/US9663488B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008105515A1 (fr) * | 2007-02-28 | 2008-09-04 | Taisho Pharmaceutical Co., Ltd. | Nouveau dérivé d'acide hydroxamique |
Non-Patent Citations (2)
Title |
---|
M N ZEMTSOVA ET AL: "SEARCH FOR NEW DRUGS SYNTHESIS AND ANTIVIRAL ACTIVITY OF 4-QUINOLINECARBOXYLIC ACID HYDRAZIDES Translated from Khimiko-Farmatsevticheskii", 1 October 2008 (2008-10-01), pages 21 - 23, XP055280466, Retrieved from the Internet <URL:http://rd.springer.com/content/pdf/10.1007/s11094-009-0187-1.pdf> * |
See also references of WO2014117090A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2014209107A1 (en) | 2015-08-06 |
CA2898615A1 (fr) | 2014-07-31 |
AU2014209107B2 (en) | 2018-04-12 |
US20150353546A1 (en) | 2015-12-10 |
US9663488B2 (en) | 2017-05-30 |
WO2014117090A1 (fr) | 2014-07-31 |
EP2948450A1 (fr) | 2015-12-02 |
JP2016508487A (ja) | 2016-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2948450A4 (fr) | Composés inhibiteurs de métalloenzyme | |
HK1220442A1 (zh) | 抑制劑 | |
HK1211921A1 (en) | Inhibitor compounds | |
EP2804479A4 (fr) | Composés inhibiteurs de métalloenzyme | |
EP3008051A4 (fr) | Composés inhibiteurs de métallo-enzymes | |
AP2015008713A0 (en) | Tetrahydropyrrolothiazine compounds | |
EP2894981A4 (fr) | Composés inhibiteurs de métallo-enzymes | |
GB201302927D0 (en) | Compounds | |
PL2804858T3 (pl) | Związki - inhibitory metaloenzymu | |
HK1216531A1 (zh) | 新的抑制劑 | |
GB201317609D0 (en) | Inhibitor compounds | |
HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
HK1222848A1 (zh) | 用作 抑制劑的吡咯並三嗪 | |
AP3850A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
EP3010923A4 (fr) | Composés de pyrroloquinazoline | |
EP2948457A4 (fr) | Composés | |
GB201306794D0 (en) | Compounds | |
GB201211019D0 (en) | Inhibitor compounds | |
GB201321328D0 (en) | Inhibitor compounds | |
TWI561515B (en) | Metalloenzyme inhibitor compounds | |
GB201305503D0 (en) | Inhibitor | |
GB201309015D0 (en) | Compounds | |
GB201308975D0 (en) | Compounds | |
GB201308409D0 (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150825 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/4375 20060101AFI20160622BHEP Ipc: A61P 9/00 20060101ALI20160622BHEP Ipc: A61P 35/00 20060101ALI20160622BHEP Ipc: A61K 31/496 20060101ALI20160622BHEP Ipc: A61K 31/541 20060101ALI20160622BHEP Ipc: C07D 471/04 20060101ALI20160622BHEP Ipc: A61P 29/00 20060101ALI20160622BHEP Ipc: C07D 215/52 20060101ALI20160622BHEP Ipc: C07D 401/04 20060101ALI20160622BHEP Ipc: A61K 31/5377 20060101ALI20160622BHEP Ipc: A61K 31/47 20060101ALI20160622BHEP Ipc: A61K 31/4545 20060101ALI20160622BHEP Ipc: A61K 31/444 20060101ALI20160622BHEP Ipc: C07D 215/14 20060101ALI20160622BHEP Ipc: A61K 31/4709 20060101ALI20160622BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20161010 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 9/00 20060101ALI20161004BHEP Ipc: A61K 31/4375 20060101AFI20161004BHEP Ipc: A61K 31/444 20060101ALI20161004BHEP Ipc: A61K 31/4545 20060101ALI20161004BHEP Ipc: C07D 215/52 20060101ALI20161004BHEP Ipc: C07D 471/04 20060101ALI20161004BHEP Ipc: A61K 31/5377 20060101ALI20161004BHEP Ipc: A61P 35/00 20060101ALI20161004BHEP Ipc: A61K 31/47 20060101ALI20161004BHEP Ipc: A61P 29/00 20060101ALI20161004BHEP Ipc: A61K 31/496 20060101ALI20161004BHEP Ipc: C07D 401/04 20060101ALI20161004BHEP Ipc: C07D 215/14 20060101ALI20161004BHEP Ipc: A61K 31/4709 20060101ALI20161004BHEP Ipc: A61K 31/541 20060101ALI20161004BHEP |
|
17Q | First examination report despatched |
Effective date: 20170720 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VIAMET PHARMACEUTICALS (NC), INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190122 |